4 options
New treatments for addiction : behavioral, ethical, legal, and social questions / Committee on Immunotherapies and Sustained-Release formations for Treating Drug Addiction ; Henrick J. Harwood and Tracy G. Myers, editors.
- Format:
- Book
- Language:
- English
- Subjects (All):
- National Institute on Drug Abuse.
- Substance abuse--Treatment.
- Substance abuse.
- Substance abuse--Chemotherapy.
- Immunotherapy.
- Medical care, Cost of.
- Medical policy.
- Informed consent (Medical law).
- Substance-Related Disorders--therapy.
- Delayed-Action Preparations--therapeutic use.
- Substance-Related Disorders--psychology.
- Immunotherapy--legislation & jurisprudence.
- Immunotherapy--ethics.
- Clinical Trials as Topic.
- Health Care Costs.
- Health Policy.
- Informed Consent.
- United States.
- Medical Subjects:
- National Institute on Drug Abuse.
- Substance-Related Disorders--therapy.
- Delayed-Action Preparations--therapeutic use.
- Substance-Related Disorders--psychology.
- Immunotherapy--legislation & jurisprudence.
- Immunotherapy--ethics.
- Clinical Trials as Topic.
- Health Care Costs.
- Health Policy.
- Informed Consent.
- United States.
- Physical Description:
- 1 online resource (320 p.)
- Edition:
- 1st ed.
- Place of Publication:
- Washington, D.C. : National Academies Press, c2004.
- Washington, DC : National Academies Press, 2004.
- Language Note:
- English
- Summary:
- This report is the work of the Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction. The committee was established in 2002 by the National Academies in response to a request from the National Institute on Drug Abuse (NIDA). NIDA is funding the development of new types of medications to treat drug addiction and sought the advice of the National Research Council and Institute of Medicine about the behavioral, ethical, legal, and social issues likely to arise as a result of the unique characteristics of these medications, if and when they become available. The charge to the committee was to identify issues that will be raised in determining who should be given these medications and under what circumstances, given the fundamental issue of therapeutic safety. This study was not intended to be a safety review of immunotherapies and sustained-release formulations, which are still under development. However, safety formed a necessary backdrop for all of the issues the committee considered.
- Contents:
- Introduction and background
- Clinical trials
- Treatment, financing, and costs
- Behavioral responses and consent.
- Notes:
- Bibliographic Level Mode of Issuance: Monograph
- Includes bibliographical references.
- Description based on publisher supplied metadata and other sources.
- ISBN:
- 9786610176519
- 9780309166652
- 0309166659
- 9781280176517
- 1280176512
- OCLC:
- 60779272
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.